WATCH: IP deal-making in life sciences—valuation, due diligence, and transaction strategies
John Rearick and Sarah Hogan, Partners at Cooley, co-moderate a panel featuring Mark Shtilerman, Senior Counsel at Deerfield Management; Jennifer Burdman, Managing Director at Sauvegarder Investment Management; and Kumar Govindaswamy, Head of Intellectual Property at Kymera Therapeutics.The panel explores best practices for IP due diligence, identifying critical red flags and risk mitigation strategies essential for life sciences M&A. They consider complex valuation methodologies, particularly for emerging modalities, platform technologies, and AI-enabled drug discovery tools.The discussion also addresses the mechanics of structuring successful transactions in a constrained capital market, covering the negotiation of term sheets, milestones, and university tech transfer partnerships that secure foundational IP assets.
